3B BlackBio Dx concludes Q1-FY27 review meeting with Marcellus
- 3B BlackBio Dx held a one-on-one meeting with Marcellus Investment Managers
- The session took place on September 16, 2026, from 11:00 am to 12:00 pm
- Management discussed Q1-FY27 results using previously disclosed materials
- No unpublished price-sensitive information was shared during the call
*this image is generated using AI for illustrative purposes only.
3B BlackBio Dx concluded its virtual one-on-one investor meeting with Marcellus Investment Managers on Wednesday, September 16, 2026. The session ran from 11:00 am to 12:00 pm India Time.
The company disclosed the outcome pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Management confirmed that only information available in the public domain was shared. No unpublished price-sensitive information was disclosed during the interaction.
Meeting Details
The engagement was classified as a single institution meeting. The company reiterated details from its Q1-FY27 Investor Presentation, which was earlier intimated to stock exchanges vide Ref. No. P-66/2026-27/27 dated August 13, 2026.
| Parameter | Details |
|---|---|
| Date | September 16, 2026 |
| Time | 11:00 am to 12:00 pm |
| Counterparty | Marcellus Investment Managers |
| Mode | Virtual |
| Type | One-on-one |
Presentation Material
The discussion centered on the financial results for the quarter ended June 30, 2026. The company provided a web link to the presentation placed before investors. This document remains consistent with the version filed in August 2026.
Historical Stock Returns for 3B BlackBio DX
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.50% | -10.10% | +11.38% | +0.49% | +0.49% | +0.49% |
How might Marcellus Investment Managers' engagement with BlackBio Dx signal broader institutional sentiment towards the Indian diagnostic sector in FY27?
What specific growth drivers from the Q1-FY27 results are likely to influence BlackBio Dx's valuation multiples in the upcoming quarters?
Could this one-on-one meeting indicate potential changes in BlackBio Dx's institutional ownership structure or future capital raising plans?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
